Singapore Markets close in 5 hrs 35 mins

Glycoprotein 41, Pipeline Review, H2 2019 - Frontier Biotechnologies Inc, Mymetics Corp, Novodux & Protheragen Inc -

The "Glycoprotein 41 (gp41) - Pipeline Review, H2 2019" drug pipelines has been added to's offering.


According to the recently published report 'Glycoprotein 41 (gp41) - Pipeline Review, H2 2019'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 20 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

The report 'Glycoprotein 41 (gp41) - Pipeline Review, H2 2019' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).


  • The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
  • The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Glycoprotein 41 (gp41) - Overview
  • Glycoprotein 41 (gp41) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glycoprotein 41 (gp41) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
  • Frontier Biotechnologies Inc
  • Longevity Biotech Inc
  • Minka Therapeutics SA
  • Molecular Express Inc
  • Mymetics Corp
  • Navigen Inc
  • Novodux
  • Osel Inc
  • Protheragen Inc
  • Sanofi Pasteur SA
  • Glycoprotein 41 (gp41) - Drug Profiles
  • albuvirtide LAR - Drug Profile
  • CPT-31 - Drug Profile
  • DS-007 - Drug Profile
  • HIV-1 vaccine - Drug Profile
  • human immunodeficiency virus (virus like particles) vaccine - Drug Profile
  • LBT-5001 - Drug Profile
  • Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
  • Monoclonal Antibody to Inhibit GP41 for HIV Infections - Drug Profile
  • Monoclonal Antibody to Target GP41 for HIV Infections - Drug Profile
  • MPER-656 - Drug Profile
  • MYMV-101 - Drug Profile
  • MYMV-201 - Drug Profile
  • Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
  • Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
  • Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
  • Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
  • Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
  • VAC-02 - Drug Profile
  • VAC-3S - Drug Profile
  • VCP-2438 - Drug Profile
  • Glycoprotein 41 (gp41) - Dormant Products
  • Glycoprotein 41 (gp41) - Discontinued Products
  • Glycoprotein 41 (gp41) - Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900